Kanya Rajangam
President, Head of Research & Development and Chief Medical OfficerDr. Kanya Rajangam, M. D., Ph. D., had been Independent Director of Turnstone Biologics Corp. since November 2021 until August 11, 2025. Dr. Rajangam serves as Head of Research & Development and Chief Medical Officer at Senti Biosciences Holdings, Inc. (formerly known as Senti Biosciences, Inc.) since March 2023 and serves as its President Since May 14, 2024 and served as its Chief Medical and Development Officer from July 2022 until March 2023. Dr. Rajangam had been the Chief Medical Officer of Nkarta, Inc. since joining in December 2018 until May 2022 and served as its Senior Vice President from December 2018 to September 2019. Dr. Rajangam served as Chief Medical Officer and Senior Vice President of Atara Biotherapeutics, Inc. since August 22, 2017 until September 2018. Dr. Rajangam served as the Chief Medical Officer of Cleave Biosciences, Inc. from December 2016 to July 2017. Dr. Rajangam was Chief medical officer of Cleave Biosciences, where she led oncology clinical development programs. Dr. Rajangam served as a Vice President of Clinical Development at Cleave Biosciences, Inc. from June 2015 to December 2016. She was a research scientist at Baxter Healthcare, Incorporated from November 2006 to December 2007. Dr. Rajangam served as a Senior Medical Director at Onyx Pharmaceuticals from April 2011 to February 2015. For nearly a decade, Dr. Rajangam has played a key role in the clinical development and regulatory submissions of new oncology drugs including the approval of KYPROLIS® (carfilzomib) for patients with multiple myeloma at Onyx Pharmaceuticals. Dr. Rajangam served as Associate Medical Director at Exelixis Inc., Incorporated from January 2008 to April 2011 in positions of increasing responsibility, including as Associate Medical Director. Throughout her career, Dr. Rajangam has worked closely with pharmaceutical Partners including Amgen, Sanofi, Bristol-Myers Squibb and Genentech to advance oncology programs in all phases of clinical development. She served as Executive Director of the Oncology and Immune-Oncology Program at Nektar Therapeutics from March 2015 to May 2015. Dr. Rajangam serves on the Board of Directors of Turnstone Biologics. After earning medical degree from St. John's Medical College in Bangalore University in 1996, India, Dr. Rajangam completed a surgical residency at the Postgraduate Institute of Medical Education and Research, India. She received a Ph. D. in biomedical engineering and tissue engineering from Northwestern University in 2006. Since January 2023, Dr. Rajangam has served as a member of the scientific advisory board of Vibe Bio, a privately held rare diseases company.
Positions
- Company NameSenti Biosciences Holdings, Inc.Stock CodeSNTIPositionPresident, Head of Research & Development and Chief Medical OfficerColleagues
- TKTimothy K. LuCo-Founder, CEO & Director
- JJJames J. CollinsScientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
- JCJay CrossChief Financial Officer
- FSFaraz SiddiquiSenior Vice President of Technical Operations
- FDFrances D. SchulzIndependent Director
- MAMichael AndreeffMember of Scientific Advisory Board
- MKMichael KalosMember of Scientific Advisory Board
